Holding(s) in Company

RNS Number : 8466E

Immupharma PLC

21 July 2016

 

RNS : FOR IMMEDIATE RELEASE

21 JULY 2016

ImmuPharma PLC

("ImmuPharma" or the "Company")

TR1 NOTIFICATION OF MAJOR INTEREST BY AVIVA

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Aviva plc ("Aviva"). Aviva's holding in ImmuPharma is now confirmed at a total of 11,169,942 Ordinary Shares which equates to a current position in the Company of 9.17%.

Full disclosure of the TR1 is shown below:

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii			ImmuPharma plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights				√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii		Aviva plc & its subsidiaries
4. Full name of shareholder(s)  (if different from 3.):iv		Registered Holder: BNY Norwich Union Nominees Limited 628,858* Chase (GA Group) Nominees Limited 7,696,271* State Street Nominees Limited 1,413,511* *denotes direct interest   Chase (GA Group) Nominees Limited 627,539 Chase Nominees Limited 275,292 Vidacos Nominees Limited 528,471
5. Date of the transaction and date on which the threshold is crossed or reached: v		19 July 2016
6. Date on which issuer notified:		20 July 2016
7. Threshold(s) that is/are crossed or reached: vi, vii		8% to 7% Change at Direct Interest Level

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction				Resulting situation after the triggering transaction
	Number of Shares		Number of Voting Rights		Number of shares	Number of voting rights		% of  voting rights x
					Direct	Direct xi	Indirect xii	Direct		Indirect
Ordinary Shares GB0033711010	11,224,776		11,224,776		11,169,942	9,738,640	1,431,302	7.997%		1.175%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument		Expiration date xiii		Exercise/ Conversion Period xiv		Number of voting rights that may be acquired if the instrument is exercised/ converted.			% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date xvii	Exercise/ Conversion period xviii	Number of voting rights instrument refers to	% of voting rights xix, xx

Total (A+B+C)
Number of voting rights	Percentage of voting rights
11,169,942	9.172%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:- Aviva Investors Global Services Limited: ·      Aviva plc (Parent Company) ·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) ·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
10. Name of the proxy holder:		See Section 4
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:	Figures are based the revised total number of voting rights of 121,781,219 as per the recent Confirmation of EIS and VCT Qualifying Status and Issue of Equity announcement of 01 March 2016.
14. Contact name:	James Clark, Aviva plc
15. Contact telephone number:	01603 683853

-Ends-

For further information please contact: ImmuPharma plc (www.immupharma.org) + 44 (0) 20 7152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations Twitter: @immupharma         + 44 (0) 7721 413496 Panmure, Gordon & Co., (NOMAD & Broker) [phone] Fred Walsh, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking Northland Capital Partners Limited (Joint Broker) Patrick Claridge, David Hignell, Corporate Finance Rob Rees, Corporate Broking [phone]

 

END

 

 

HOLDFLBLQDFLBBV